Studies evaluating children (cohorts followed up from birth)
| First author | Year of publication | Study location | Total number of participants | % HIV+ | % HIV+ on ART | Duration of follow-up (from birth) | Respiratory data collected | Notes/comments |
|---|---|---|---|---|---|---|---|---|
| Spira17 | 1999 | Rwanda | 401 | 13 | 0 | Median 27 months (HIV-positive group), 51 months (HIV-negative group) | Chronic cough (>14 days) | Measured cumulative incidence of developing a cough lasting >14 days |
| Olayinka18 | 1999 | Zimbabwe | 272 | 16 | 0 | 24 months | Persistent cough | |
| Taha20 | 2000 | Malawi | 689 | 19 | 0 | Median 18 months | Cough since last review | 2 HIV-negative groups—exposed uninfected infants and unexposed. Rate of cough the same in each. |
| Galli22 | 2003 | Italy | 280 | 75 | 25 | 24 months | History of wheezy illness collected at clinic appointments | Presents proportion of infants with wheezy illness in first 2 years of life |
| Read24 | 2009 | Malawi, Tanzania, Zambia | 1317 | 84 | 0 | 12 months | Retraction of intercostal muscles, wheezes, cough, active nasal flaring or rales at follow-up visits | HPTN 024 study cohort, studied 2001–2004 |
ART, antiretroviral therapy; HPTN, The HIV Prevention Trials Network.